Johnson & Johnson wins reimbursement for Rybrevant cancer therapy in Canada
Sundry Photography/iStock Editorial via Getty Images
- Johnson & Johnson’s (NYSE:JNJ) Janssen unit announced Thursday a favorable reimbursement decision from Canada regarding its Rybrevant (amivantamab) lung cancer therapy.
- The bispecific antibody is indicated as a second-line option for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.
- The company said that Canadian Agency for Drugs and Technologies in Health (CADTH) endorsed the public reimbursement of Rybrevant for the approved indication in patients whose cancer had advanced despite platinum-based chemotherapy.
- About 15% of Canadians with non-squamous NSCLC harbor the activating EGFR mutation. An estimated third of those cases indicate EGFR Exon 20 insertion mutations, which are linked to worse clinical outcomes compared to those with more prevalent EGFR mutations.
- Read: Despite a ~10% decline in its value since his last article on JNJ, Seeking Alpha contributor Daniel Schönberger reaffirmed his Hold rating on the stock this week, citing valuation concerns.